PTCT

39.23

0.00% 0.00

Dopo l'orario di chiusura: 39.23

Ptc Therapeutics Inc (PTCT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PTCT Giù? Forum Previsione

Precedente Chiudi:

$39.23

Aprire:

$39.14

Volume 24 ore:

429.62K

Relative Volume:

0.65

Capitalizzazione di mercato:

$3.37B

Reddito:

$900.45M

Utile/perdita netta:

$-479.52M

Rapporto P/E:

-4.5353

EPS:

-8.65

Flusso di cassa netto:

$-230.14M

1 W Prestazione:

-12.57%

1M Prestazione:

+0.33%

6M Prestazione:

+18.54%

1 anno Prestazione:

+91.74%

Intervallo 1D:

$38.65

$39.86

Intervallo di 1 settimana:

$38.65

$45.65

Portata 52W:

$20.50

$46.98

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Nome

Ptc Therapeutics Inc

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

(908) 222-7000

Indirizzo

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Dipendente

Cinguettio

@PTCBio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

PTCT's Discussions on Twitter

Confronta PTCT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PTCT	39.23	3.37B	900.45M	-479.52M	-230.14M	-8.65
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-10-30	Aggiornamento	Oppenheimer	Perform → Outperform
2023-10-27	Downgrade	Citigroup	Neutral → Sell
2023-10-06	Downgrade	Truist	Buy → Hold
2023-09-18	Downgrade	Citigroup	Buy → Neutral
2023-09-15	Downgrade	Raymond James	Outperform → Underperform
2023-03-17	Iniziato	SVB Securities	Market Perform
2022-12-14	Iniziato	Goldman	Sell
2022-09-12	Iniziato	Jefferies	Buy
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-09-01	Iniziato	Citigroup	Buy
2022-04-04	Ripresa	Cantor Fitzgerald	Overweight
2021-10-18	Downgrade	BofA Securities	Neutral → Underperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-29	Aggiornamento	RBC Capital Mkts	Underperform → Sector Perform
2021-02-12	Downgrade	BofA Securities	Buy → Neutral
2021-01-05	Aggiornamento	Citigroup	Neutral → Buy
2020-11-30	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
2020-10-30	Downgrade	Citigroup	Buy → Neutral
2020-10-28	Iniziato	UBS	Neutral
2020-10-07	Aggiornamento	JP Morgan	Neutral → Overweight
2020-08-25	Iniziato	Raymond James	Outperform
2020-04-09	Aggiornamento	Citigroup	Neutral → Buy
2020-02-20	Downgrade	Citigroup	Buy → Neutral
2020-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-11-12	Iniziato	SunTrust	Buy
2019-05-13	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-04-11	Iniziato	Bernstein	Outperform
2018-10-03	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-07-19	Iniziato	Credit Suisse	Outperform
2018-06-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-04-04	Downgrade	Barclays	Equal Weight → Underweight
2018-01-29	Ripresa	RBC Capital Mkts	Sector Perform
2017-11-16	Aggiornamento	JP Morgan	Underweight → Neutral
2017-10-26	Downgrade	BofA/Merrill	Neutral → Underperform
2017-10-09	Downgrade	JP Morgan	Neutral → Underweight

Mostra tutto

Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie

Nov 16, 2024

PTC Therapeutics (NASDAQ:PTCT) Shares Down 7.4%Time to Sell? - MarketBeat

Nov 16, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Additional Shares in PTC Therape - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

PTC Therapeutics wins FDA nod for gene therapy - MSN

Nov 14, 2024

PTC Gets US FDA Approval For Brain-Delivered Gene Therapy - Citeline

Nov 14, 2024

PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain - MedCity News

Nov 14, 2024

FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain - AOL

Nov 14, 2024

AADC deficiency gene therapy, called Kebilidi, now approved in US - AADC News

Nov 14, 2024

FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency - Pharmacy Times

Nov 14, 2024

PTC Therapeutics' Gene Therapy For AADC Deficiency Approved By FDA - Contract Pharma

Nov 14, 2024

FDA grants accelerated approval for PTC’s AADC deficiency gene therapy - Pharmaceutical Technology

Nov 14, 2024

PTC Therapeutics wins FDA nod for gene therapy (PTCT:NASDAQ) - Seeking Alpha

Nov 14, 2024

PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease - BioSpace

Nov 14, 2024

PTC gets FDA okay for first brain-delivered gene therapy - pharmaphorum

Nov 14, 2024

Nov 13, 2024

US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder - Reuters.com

Nov 13, 2024

PTC Therapeutics Wins FDA Approval for Groundbreaking Brain Gene Therapy KEBILIDI | PTCT Stock News - StockTitan

Nov 13, 2024

PTC Therapeutics's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Canada

Nov 13, 2024

Nov 11, 2024

Barclays Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat

Nov 11, 2024

Nov 09, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 09, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $40.38 Average Target Price from Analysts - MarketBeat

Nov 09, 2024